Senior Medical Director, Stroke and Thrombosis

 

At Bayer we’re visionaries, driven to solve the world’s toughest challenges and striving for a world where 'Health for all Hunger for none’ is no longer a dream, but a real possibility. We’re doing it with energy, curiosity and sheer dedication, always learning from unique perspectives of those around us, expanding our thinking, growing our capabilities and redefining ‘impossible’. There are so many reasons to join us. If you’re hungry to build a varied and meaningful career in a community of brilliant and diverse minds to make a real difference, there’s only one choice.

 

Senior Medical Director, Stroke and Thrombosis 

 

As a critical member of the US Medical Affairs team, the Senior Medical Director, Stroke and Thrombosis will be responsible for the development and execution of high-quality medical strategy for the Stroke and Thrombosis portfolio through scientific leadership, external engagement, and cross-functional influence to advance evidence generation, medical education, and implementation-science initiatives that support the portfolio throughout its lifecycle.

 

YOUR TASKS AND RESPONSIBILITIES

 

More specifically, the Senior Medical Director, Stroke and Thrombosis, will have core responsibilities including, but not limited to:

 

External Scientific Leadership and Engagement:

 

• Develop and guide local Thought Leader (TL) management strategy, together with cross-functional partners.
• Serve as the US medical expert for asundexian engaging thought leaders, stroke centers, academic institutions, medical societies, and patient advocacy groups to advance scientific leadership and collaboration.
• Lead and support advisory board, including agenda development, faculty engagement and synthesis of insights to help inform medical strategy.
• Represent US Medical Affairs at major congresses, symposia and scientific forums.
• Participate and may take on active leadership in the planning and administration of activities concerned with the clinical evaluation of drugs in development for the purpose of obtaining an approved Investigational New Drug (IND) or New Drug Application (NDA).

 

Medical Strategy, Evidence and Internal Leadership:

 

• Support development and execution of the US medical strategy, offering critical inputs during design and throughout the end-to-end execution of programs, in alignment with senior medical leadership.
• Collaborate cross-functionally with Global Evidence Generation, Clinical Development, Regulatory, Commercial and other medical affairs partners to develop and implement the Integrated Evidence Plans to improve the value proposition for the portfolio.
• Collaborate closely with global medical affairs team to ensure consistent scientific narrative, coordinated deployment of initiatives and transparent bi-directional insight flow.
• Provide medical leadership for scientific communications and publications, serving as a representative on cross-functional strategy teams.
• Contribute to publication planning, data interpretation, and scientific dissemination in the US.
• Active participation and effective collaboration with global teams to assure the efficient and expedient conduct of clinical development programs, aligning them with strategic priorities that support appropriate US direction of the Life Cycle Management strategy.
• Support IIR, research collaborations, Phase 4, post-marketing, post-hoc analyses, real-world evidence activities (including scientific review, study and analyses design, feasibility assessment, data interpretation, and ongoing oversight).
• Advance implementation science initiatives.
• Provide medical scientific input for brand and program documents, including integrated disease area plans, medical information documents, drug safety reporting documents, etc, while ensuring design and execution of all medical activities are according to internal and external compliance guidelines.
• Monitor and understand implications of evolving competitor landscape to inform medical strategy.
• Support completion of annual New Drug Application (NDA) reports for respective brands through evaluation of clinical data and literature and provide US Medical Affairs input in the preparation of key medical documents for INDs and NDAs. This includes ensuring appropriate US Medical Affairs input in interaction